Emzor Pharmaceutical Industries Limited, a
major player in the Nigerian Pharmaceutical sector has introduced
BIOPHIN INJECTION into the Nigerian market. With the introduction
of Biophin injection, the company has started broadening her
presence in the ethical pharmaceutical market segment.
Biophin Injection (IM/IV) is a brand of Ceftriaxone
Sodium indicated in the treatment of severe, and life-threatening
infections caused by organisms sensitive to Ceftriaxone.
Severe infections include Meningitis, Pneumonia, Sepsis, Urinary
tract infections, Ear, nose and throat infections etc.
In surgery, Biophin injection is indicated for pre-operative
surgical prophylaxis and management of surgical site infections.
Biophin is manufactured by Hanmi Pharmaceutical
Company Limited, South Korea- a technologically driven company
committed to the development of new Molecules / Processes.
An example is the development of a new synthetic process for
the manufacture of Ceftriaxone in 1987, which it licensed
in 1989 to the product innovator.
Biophin provides round the clock cover against
infections with once daily dosage and has a very good safety
profile. It is supplied with 3.5ml lidocaine as diluent for
IM injection to reduce pain at injection site, while for IV
injection dilution is made with water for injection.
In line with our corporate mission of providing
quality and affordable healthcare products to the Nigerian
people, Biophin injection is offered at an affordable price
from Emzor.
To ensure that the benefits of Biophin injection are adequately
communicated for the benefit of the patient/healthcare professionals,
the product will be aggressively detailed in Hospitals and
clinics and other centers pan Nigeria to generate massive
awareness.
The introduction of BIOPHIN injection marks
a major shift in the direction of Emzor. Plans are underway
to introduce more core ethical products to broaden the product
portfolio of Emzor Pharmaceuticals in the ethical products
segment of the market.
